Philips gets FDA nod for ultrasound for COVID-19

By staff writers

May 13, 2020 -- Philips Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration to market a range of ultrasound applications for use in patients with lung and cardiac applications related to COVID-19.

Ultrasound has become an important tool in diagnosing and managing patients with COVID-19 due to its ease of use and the ability to take scanners directly to a patient's bedside. Ultrasound scanners are also easier to disinfect after use than imaging systems like CT scanners.

The FDA clearance applies to Philips ultrasound scanners including the company's Epiq, Affiniti, Lumify, CX50, and Sparq diagnostic ultrasound scanners, as well as to off-cart solutions like Qlab advanced quantification software. It covers specific presets, transducers, quantification tools, and other capabilities that can be used to assess and manage COVID-19-related lung and cardiac complications, according to the company.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking